Celldex Therapeutics Inc (CLDX)
$25.34 -$1.11 (-4.20%) 10:04 AM 12/13/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$1.78B -
Day's Range
$25.08 - $26.62 -
Volume
1,065,884 -
52 Week Low / High
$22.93 - $53.18 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 9
- Strong Buy
- 1
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong Sell
- $59.57
- Target Price
Company News
-
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study — Sep 26th, 2024
Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for treating chronic spontaneous urticaria (CSU). CSU is a type of skin disease, character...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 — Sep 25th, 2024
Celldex Therapeutics, Inc. - 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across omalizumab-experienced/refractory/naïve disease ...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 — Sep 25th, 2024
Celldex Therapeutics, Inc. - 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across omalizumab-experienced/refractory/naïve disease ...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study — Sep 26th, 2024
Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for treating chronic spontaneous urticaria (CSU). CSU is a type of skin disease, character...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks — Oct 15th, 2024
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands against other most promising small-cap stocks. Small-Cap Stocks are Expected to Offer Higher R...
-
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study — Sep 26th, 2024
Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for treating chronic spontaneous urticaria (CSU). CSU is a type of skin disease, character...
Portfolio
Comprised of 1 portfolios